Skip to content

Denali Therapeutics Inc. DNLI Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$163.1M+169%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$450K+28.9%
uniQure logo
uniQureQURE
$550K+246%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$6.4M-59.3%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$0-100%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$4.23M+130%

Other financials

Income statement

See full
Revenue-
Operating income-$137.4M+5.6%
Net income-$128.4M+3.4%
EPS (diluted)-$0.69+11.5%

Balance sheet

See full
Cash & equivalents$390.7M+551%
Total debt$40.0M-22.3%
Total equity$926.1M-17.5%
Total assets$1.3B-0.4%

Cash flow

See full
Operating cash flow-$131.2M+0.2%
CapEx$2.5M-51.4%
Free cash flow-$133.7M+2.1%

Valuation

See full
Market cap$3.93B+54.2%

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-49.6%+34.2pp
Debt / equity0.0×
Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Denali Therapeutics Inc.'s stock issuance proceeds?
Denali Therapeutics Inc. (DNLI) reported stock issuance proceeds of $12.37M in Q1 2026.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.